Anbio Biotechnology (NNNN) Non-Current Receivables (2023)
Anbio Biotechnology's quarterly Non-Current Receivables came in at $18009.0 in Q4 2023.
Anbio Biotechnology has reported Non-Current Receivables for 1 years, with the latest figure at $18009.0 in Q4 2023.
- For the quarter ending Q4 2023, Non-Current Receivables changed N/A year-over-year to $18009.0; the trailing twelve-month figure through Dec 2023 stood at $18009.0 (changed N/A YoY), and the FY2023 full-year result was $18009.0, changed N/A from the prior year.
- Non-Current Receivables for Q4 2023 stood at $18009.0.
- The five-year high for Non-Current Receivables was $18009.0 in Q4 2023, with the low at $18009.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 156.17 Bn | 151.78 Bn | 1.83 Bn | - |
| 2 | Becton Dickinson | 41.51 Bn | 40.49 Bn | 2.15 Bn | - |
| 3 | Resmed | 30.43 Bn | 28.77 Bn | 890.98 Mn | - |
| 4 | West Pharmaceutical Services | 22.78 Bn | 22.26 Bn | 296.40 Mn | - |
| 5 | Solventum | 13.39 Bn | 13.39 Bn | 1.10 Bn | - |
| 6 | Cooper Companies | 12.33 Bn | 12.20 Bn | 695.20 Mn | - |
| 7 | Align Technology | 11.65 Bn | 10.59 Bn | 736.59 Mn | - |
| 8 | Baxter International | 9.81 Bn | 7.77 Bn | 891.00 Mn | - |
| 9 | Aptargroup | 7.39 Bn | 7.19 Bn | 351.91 Mn | - |
| 10 | Anbio Biotechnology | 1.32 Bn | 1.31 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 18,009.00 |